Physician profile
Brian D Smith
NPI 1669458162
$9,654.39
in general payments reported to CMS, 2019-2025
25 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $61.90 · 2021: $1,014 · 2022: $4,351 · 2023: $1,494 · 2024: $1,103 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,897.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,349.27 | 2021-2022 | |
| Abbvie INC. | $1,851.61 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Alphagan P |
| Alcon Vision LLC | $1,791.74 | 2019-2025 | Clareon, Lensx, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $829.40 | 2021-2023 | Tecnis Iol, Tecnis Iol |
| Sight Sciences, INC. | $658.18 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $351.78 | 2023-2024 | Ic-8 Apthera Iol, Miebo |
| Biotissue Holdings INC. | $323.03 | 2019-2025 | |
| Rxsight INC | $278.11 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Ivantis, INC | $204.59 | 2020-2021 | |
| Glaukos Corporation | $161.27 | 2024 | Idose |
| Kala Pharmaceuticals, INC. | $151.71 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $145.09 | 2022 | |
| Ocular Therapeutix, INC. | $116.91 | 2022-2023 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $69.68 | 2022 | |
| Amgen INC. | $48.52 | 2025 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $47.49 | 2024 | Mako |
| Dompe US, INC. | $46.86 | 2019-2024 | Oxervate |
| Ani Pharmaceuticals, INC. | $43.58 | 2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $39.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.60 | 2019 | |
| Shire North American Group INC | $24.00 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.02 | 2024 | Eohilia |
| Mallinckrodt Enterprises LLC | $20.95 | 2019 | |
| Genentech USA, INC. | $17.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.